{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:03:47Z","timestamp":1791911027913,"version":"4.3.4"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-183813"],"award-info":[{"award-number":["PJT-183813"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejmech.2025.117579","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T18:14:29Z","timestamp":1743358469000},"page":"117579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Optimizing the pharmacokinetics and selectivity of TMPRSS2 inhibitors"],"prefix":"10.1016","volume":"294","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2890-6528","authenticated-orcid":false,"given":"S\u00e1ra","family":"Ferkov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Lepage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5081-5564","authenticated-orcid":false,"given":"Antoine","family":"D\u00e9silets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Assouvie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Lemieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Brochu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Froehlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Gravel-Trudeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jules","family":"Vastra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Jean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7627-701X","authenticated-orcid":false,"given":"Philippe","family":"Sarret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-8003","authenticated-orcid":false,"given":"Richard","family":"Leduc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2032-7970","authenticated-orcid":false,"given":"Pierre-Luc","family":"Boudreault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117579_bib1","first-page":"157","article-title":"WHO declares COVID-19 a pandemic","volume":"91","author":"Cucinotta","year":"2020","journal-title":"Acta Biomed."},{"key":"10.1016\/j.ejmech.2025.117579_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taaa227","article-title":"Public health emergencies of international concern: a historic overview","volume":"27","author":"Wilder-Smith","year":"2020","journal-title":"J Travel Med"},{"key":"10.1016\/j.ejmech.2025.117579_bib3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.117579_bib4","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/220650b0","article-title":"Coronaviruses","volume":"220","author":"Almeida","year":"1968","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117579_bib5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.117579_bib6","author":"Wrapp"},{"key":"10.1016\/j.ejmech.2025.117579_bib7","author":"He"},{"key":"10.1016\/j.ejmech.2025.117579_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2025.117579_bib9","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41423-020-0458-z","article-title":"Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies","volume":"17","author":"Yi","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ejmech.2025.117579_bib10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117579_bib11","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","article-title":"Structural and functional basis of SARS-CoV-2 entry by using human ACE2","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117579_bib12","article-title":"Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions","volume":"117","author":"Wang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2025.117579_bib13","article-title":"Distinctive roles of furin and TMPRSS2 in SARS-CoV-2 infectivity","volume":"96","author":"Essalmani","year":"2022","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2025.117579_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41421-022-00419-w","article-title":"Novel cleavage sites identified in SARS-CoV-2 spike protein reveal mechanism for cathepsin L-facilitated viral infection and treatment strategies","volume":"8","author":"Zhao","year":"2022","journal-title":"Cell Discov"},{"key":"10.1016\/j.ejmech.2025.117579_bib15","author":"Van Marle"},{"key":"10.1016\/j.ejmech.2025.117579_bib16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ejmech.2025.117579_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.110005","article-title":"Pharmacology of COVID-19","volume":"362","author":"Sureda","year":"2022","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2025.117579_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s43856-024-00716-3","article-title":"A modeling study to define guidelines for antigen screening in schools and workplaces to mitigate COVID-19 outbreaks","volume":"5","author":"Jeong","year":"2025","journal-title":"Communications Medicine"},{"key":"10.1016\/j.ejmech.2025.117579_bib19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3201\/eid1002.030759","article-title":"Real-time reverse transcription\u2013polymerase chain reaction assay for SARS-associated coronavirus","author":"Emery","year":"2004","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.117579_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/infdis\/jiac317","article-title":"Sensitivity of reverse transcription polymerase chain reaction tests for severe acute respiratory syndrome coronavirus 2 through time","volume":"227","author":"Binny","year":"2023","journal-title":"JID (J. Infect. Dis.)"},{"key":"10.1016\/j.ejmech.2025.117579_bib21","first-page":"1663","article-title":"COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer\/BioNTech and Moderna Vaccines","author":"Meo","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2025.117579_bib22","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1017\/S0950268821002430","article-title":"SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence","volume":"149","author":"Tatsi","year":"2021","journal-title":"Epidemiol. Infect."},{"key":"10.1016\/j.ejmech.2025.117579_bib23","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 \u2014 final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.117579_bib24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.117579_bib25","article-title":"Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.117579_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117579_bib27","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19","author":"Unoh","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117579_bib28","doi-asserted-by":"crossref","DOI":"10.1186\/s12929-021-00784-w","article-title":"Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection","volume":"29","author":"Hwang","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ejmech.2025.117579_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo0718","article-title":"Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms","volume":"14","author":"Stevens","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2025.117579_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-29104-y","article-title":"De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report","volume":"13","author":"Gandhi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117579_bib31","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","article-title":"Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir","volume":"613","author":"Iketani","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117579_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00861-21","article-title":"Structural basis of covalent inhibitory mechanism of TMPRSS2-related serine proteases by Camostat","volume":"95","author":"Sun","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2025.117579_bib33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117579_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00754-20","article-title":"Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19","volume":"64","author":"Hoffmann","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.117579_bib35","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41586-022-04661-w","article-title":"A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic","volume":"605","author":"Shapira","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117579_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-022-03613-4","article-title":"Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture","volume":"5","author":"Wettstein","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejmech.2025.117579_bib37","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2108728118","article-title":"A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells","volume":"118","author":"Mahoney","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2025.117579_bib38","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-024-09468-w","article-title":"Safety and efficacy of Camostat mesylate for covid-19: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Khan","year":"2024","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.117579_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27061881","article-title":"Pharmacokinetics of nafamostat, a potent serine protease inhibitor, by a novel LC-MS\/MS analysis","volume":"27","author":"Oh","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.117579_bib40","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1146\/annurev-cellbio-092910-154247","article-title":"Membrane-anchored serine proteases in vertebrate cell and developmental biology","volume":"27","author":"Szabo","year":"2011","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2025.117579_bib41","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41589-022-01059-7","article-title":"Structure and activity of human TMPRSS2 protease implicated in SARS-CoV-2 activation","volume":"18","author":"Fraser","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117579_bib42","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2353\/ajpath.2009.090240","article-title":"Epithelial integrity is maintained by a matriptase-dependent proteolytic pathway","volume":"175","author":"List","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejmech.2025.117579_bib43","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1111\/j.1538-7836.2005.01456.x","article-title":"Determinants of specificity in coagulation proteases","volume":"3","author":"Page","year":"2005","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.ejmech.2025.117579_bib44","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/ng.130","article-title":"Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA)","volume":"40","author":"Finberg","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2025.117579_bib45","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1128\/JVI.02202-13","article-title":"TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein","volume":"88","author":"Heurich","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2025.117579_bib46","author":"Afar"},{"key":"10.1016\/j.ejmech.2025.117579_bib47","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.2353\/ajpath.2010.090665","article-title":"TMPRSS2, a serine protease expressed in the prostate on the apical surface of luminal epithelial cells and released into semen in prostasomes, is misregulated in prostate cancer cells","volume":"176","author":"Chen","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejmech.2025.117579_bib48","doi-asserted-by":"crossref","first-page":"12658","DOI":"10.1128\/JVI.01542-10","article-title":"Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2","volume":"84","author":"Matsuyama","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2025.117579_bib49","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1128\/JVI.02205-08","article-title":"Proteolytic activation of the 1918 influenza virus hemagglutinin","volume":"83","author":"Chaipan","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2025.117579_bib50","doi-asserted-by":"crossref","first-page":"12969","DOI":"10.1021\/acs.jmedchem.4c00922","article-title":"Rational in silico design of selective TMPRSS6 peptidomimetic inhibitors via exploitation of the S2 subpocket","volume":"67","author":"Desgagn\u00e9","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117579_bib51","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1021\/ml3000534","article-title":"Design and synthesis of potent, selective inhibitors of matriptase","volume":"3","author":"Colombo","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117579_bib52","doi-asserted-by":"crossref","first-page":"10198","DOI":"10.1021\/jm5015633","article-title":"Analysis of subpocket selectivity and identification of potent selective inhibitors for matriptase and matriptase-2","volume":"57","author":"Duch\u00eane","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117579_bib53","article-title":"Optimization of ketobenzothiazole-based type II transmembrane serine protease inhibitors to block H1N1 influenza virus replication","author":"Colombo","year":"2023","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.117579_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/pro.5110","article-title":"Use of protease substrate specificity screening in the rational design of selective protease inhibitors with unnatural amino acids: application to <scp>HGFA<\/scp> , matriptase, and hepsin","volume":"33","author":"Mahoney","year":"2024","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejmech.2025.117579_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25031375","article-title":"Ligand-based design of selective peptidomimetic uPA and TMPRSS2 inhibitors with Arg bioisosteres","volume":"25","author":"M\u00fcller","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117579_bib56","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.chembiol.2019.09.004","article-title":"Discovery and development of TMPRSS6 inhibitors modulating hepcidin levels in human hepatocytes","volume":"26","author":"B\u00e9liveau","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117579_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.105869","article-title":"Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals","volume":"225","author":"P\u00e9rez-Vargas","year":"2024","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ejmech.2025.117579_bib58","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1111\/j.1742-4658.2009.06950.x","article-title":"Probing the substrate specificities of matriptase, matriptase-2, hepsin and DESC1 with internally quenched fluorescent peptides","volume":"276","author":"B\u00e9liveau","year":"2009","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2025.117579_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-54714-5","article-title":"The impact of factor Xa inhibitors on bleeding risk in patients with respiratory diseases","volume":"14","author":"Hamada","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.117579_bib60","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s11239-021-02455-x","article-title":"Factor Xa inhibitors: critical considerations for clinical development and testing","volume":"52","author":"Becker","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.ejmech.2025.117579_bib61","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/CIRCRESAHA.112.276741","article-title":"Oral direct factor xa inhibitors","volume":"111","author":"Yeh","year":"2012","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejmech.2025.117579_bib62","article-title":"Discovery and development of factor xa inhibitors (2015\u20132022)","volume":"14","author":"Zheng","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117579_bib63","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-02498-2","article-title":"Development and validation of a high throughput whole blood thrombolysis plate assay","volume":"7","author":"Bonnard","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.117579_bib64","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.4130.4130","article-title":"In vitro evaluation of apixaban, a novel, potent, selective and orally bioavailable factor xa inhibitor","volume":"108","author":"Luettgen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117579_bib65","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2021-001785","article-title":"Combined anticoagulant and antiplatelet therapy is associated with an improved outcome in hospitalised patients with COVID-19: a propensity matched cohort study","volume":"8","author":"Matli","year":"2021","journal-title":"Open Heart"},{"key":"10.1016\/j.ejmech.2025.117579_bib66","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.chest.2020.05.559","article-title":"Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report","volume":"158","author":"Moores","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.ejmech.2025.117579_bib67","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1111\/jth.14828","article-title":"Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series","volume":"18","author":"Wang","year":"2020","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.ejmech.2025.117579_bib68","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3109\/02770903.2013.773518","article-title":"Salbutamol sulfate absorption across calu-3 bronchial epithelia cell monolayer is inhibited in the presence of common anionic NSAIDs","volume":"50","author":"Mamlouk","year":"2013","journal-title":"J. Asthma"},{"key":"10.1016\/j.ejmech.2025.117579_bib69","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/jps.21995","article-title":"Drug transporters in the lung - do they play a role in the biopharmaceutics of inhaled drugs?","volume":"99","author":"Cynthia","year":"2010","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ejmech.2025.117579_bib70","author":"Lipinski"},{"key":"10.1016\/j.ejmech.2025.117579_bib71","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117579_bib72","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1007\/s11095-006-0255-0","article-title":"Culture of Calu-3 cells at the air interface provides a representative model of the airway epithelial barrier","volume":"23","author":"Grainger","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejmech.2025.117579_bib73","doi-asserted-by":"crossref","unstructured":"J.E. McGreig, K.-M. McLaughlin, S.G. Masterson, M. Widera, V. Kr\u00e4hling, S. Ciesek, M.N. Wass, J. Cinatl jr, SARS-CoV-2 and SARS-CoV differ in their cell tropism and drug 1 sensitivity profiles 2 Denisa Bojkova 1#, (n.d.). https:\/\/doi.org\/10.1101\/2020.04.03.024257.","DOI":"10.1101\/2020.04.03.024257"},{"key":"10.1016\/j.ejmech.2025.117579_bib74","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00754-20","article-title":"Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19","volume":"64","author":"Hoffmann","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.117579_bib75","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.4c02468","article-title":"From N\u20110385 to N\u20110920: Unveiling a Host-Directed Protease Inhibitor with Picomolar Antiviral Efficacy against Prevalent SARS-CoV\u20112 Variants","author":"Lemieux","year":"2025","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425003447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425003447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T05:11:53Z","timestamp":1765602713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425003447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":75,"alternative-id":["S0223523425003447"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117579","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing the pharmacokinetics and selectivity of TMPRSS2 inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117579","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117579"}}